OXYGENATE

Oxylipins signature to monitor the cardiometabolic status and its response to dietary intervention

Project description

Background and aim 

There is an urgent need to find reliable early biomarkers of the cardiometabolic syndrome (CardMetS) allowing intervention before irreversible damage develops while assessing the efficacy of nutritional prevention. Oxylipins could be relevant candidate biomarkers thanks to their involvement in the homeostatic regulation of various process related to the cardiometabolic status and the consistent link reported between diet, oxylipins and cardiometabolic dysregulations. Moreover, the oxylipin profiling could provide a mechanistic signature at the metabolite level allowing a better stratification of patients at risk of cardiometabolic diseases (CVD and diabetes).

Our main objective in the OXYGENATE project was to uncover and validate the oxylipin signatures reflecting the cardiometabolic status or its early transition towards the CardMetS. To achieve this goal, we proposed a multidisciplinary project involving experts in lipidomics, nutrition and epidemiology and combining the comprehensive and quantitative lipidomic profiling of circulating oxylipins and the use of different biobanks from large prospective cohorts and different whole-diet interventions.

Overall achievements

The OXYGENATE project started with the optimization of the MS-based targeted lipidomic profiling of oxylipins. The optimized method developed allows a comprehensive profiling of all types of oxylipins including the free and the esterified forms. The method has been validated through a round robin test involving 5 different laboratories worldwide and allowing to determine for each oxylipin (i) intra- and inter-day variabilities and (ii) consensus values and their respective dispersion. The OXYGENATE consortium also provided a detailed SOP for sample storage and preparation including quantitative and qualitative data regarding oxylipin stability. Using this original method, we have generated the oxylipin profiles of over 1000 participants involved in various independent studies (cross-sectional and longitudinal observational studies and intervention studies) performed in four different populations (Polish, French, Danish and American). So far, the cross-sectional studies nested in the Polish branch of the PURE cohort and the French Nutrinet-Santé cohort lead to the identification of a signature of 23 oxylipins coined OxyScore. This score is highly discriminant of CardMetS and has high performances of classification and replicability. Moreover, the identified oxylipins provide a unique mechanistic signature of MetS that may enhance the prediction of cardiometabolic diseases risk. Complementary cross-sectional studies nested in the same cohorts have been performed to investigate the links between the OxyScore and diet. Moreover, to further validate the OxyScore, we have tested its ability to monitor the changes of cardiometabolic health in response to diet using the biocollection collected in two independent studies (the Danish SHOPUS study and the American iMAPS study).

Expected impacts

On completion, the OXYGENATE project has (i) provided an internationally validated method of comprehensive oxylipins profiling (ii) generated the 1st large diet- and health-related oxylipins database, (iii) identified and validated the oxylipins reflecting the cardiometabolic status and the quality of dietary patterns (biostatistics under progress) (iv) provided a proof-of-concept of the ability of oxylipins to monitor the effect of diet on the cardiometabolic status (biostatistics under progress). It is expected that the oxylipins identified and validated will allow a better detection and management of the cardiometabolic diseases.

Consortium

Partner Organization Partner Country
Centre de Recherche en Épidémiologies France
University of Copenhagen Denmark
University of Wuppertal Germany
Wroclaw Medical University Poland
USDA/UC Davis USA

Highlights

In the framework of the JPI-Oxygenate project we have:

  1. Standardized and validated a MS-based method for the quantitative analysis of over 130 oxylipins including all species found in the free form and esterified into complex circulating lipids.
  2. Showed that total plasma oxylipins (sum of free and esterified) are stable regarding delays during plasma generation and long-term storage at −80°C.
  3. Showed that our MS-based method for the quantitative analysis of total oxylipins in plasma has a low technical variability and allow reliable, reproducible and comparable oxylipin concentrations in independent laboratories.
  4. Identified an oxylipin signature of cardiometabolic syndrome having high performances of classification and replicability.
  5. Showed that the oxylipin signature of cardiometabolic syndrome provides a unique mechanistic phenotyping informing on crucial molecular pathways that may help identify patients at high risk of cardiometabolic diseases.

Products

Title: MS-based targeted metabolomics of eicosanoids and other oxylipins: Analytical and inter-individual variabilities
Author: Cécile Gladine*, Annika I. Ostermann*, John W. Newman*, Nils Helge Schebb*
Link: https://doi.org/10.1016/j.freeradbiomed.2019.05.012
Title: Stability of oxylipins during plasma generation and long-term storage
Author: Elisabeth Koch*, Malwina Mainka*, Céline Dalle*, Annika I. Ostermann*, Katharina M. Rund*, Laura Kutzner*, Laura-Fabienne Froehlich*, Justine Bertrand-Michel*, Cécile Gladine*, Nils Helge Schebb*
Link: https://doi.org/10.1016/j.talanta.2020.121074
Title: Malwina Mainka*, Céline Dalle*, Mélanie Pétéra*, Jessica Dalloux-Chioccioli*, Nadja Kampschulte*, Annika I. Ostermann*, Michael Rothe*, Justine Bertrand-Michel*, John W. Newman*, Cécile Gladine*, and Nils Helge Schebb*
Author: Harmonized procedures lead to comparable quantification of total oxylipins across laboratories
Link: https://doi.org/10.1194/jlr.RA120000991
Title: The clinical translation of eicosanoids and other oxylipins, although challenging, should be actively pursued
Author: Cécile Gladine* and Maria Fedorova
Link: https://doi.org/10.1016/j.jmsacl.2021.08.003

Reports


Endreport

At this stage, we have two main conclusions. The first one is related to the analytical aspects of the project that are of upmost importance in the field of biomarker discovery and validation. We have showed that although challenging, the quantitative analysis of oxylipins can be achieved with low technical variability, high reliability and comparability provided that a standardized and harmonized operative procedure is followed. The second main conclusion is related to the phenotyping of cardiometabolic syndrome that need to go deeper in the molecular pathways. The comprehensive profiling of oxylipins allows such a mechanistic phenotyping and could help clinicians to better understand, stratify and ultimately prevent the risk of cardiometabolic diseases. We are currently in the process of completing the analysis of the links between oxylipins and diet that should bring new conclusions concerning the potential of oxylipins as mediators of the effects of diet on cardiometabolic health. This will answer one of the main objective of the JPI-HDHL that is to understand the relationship between diet and health.

Based on these two main conclusions, a first follow-up research will be to extend the interlaboratory comparison of our MS-based oxylipin profiling method to other labs of the lipidomics community in order to promote the harmonization of oxylipin profiling and to generate high quality open-access databases for future health-related association studies. Concerning the identified oxylipin signature, although we provided first evidence of its replicability, we recommend further validation in various and larger-scale population studies to confirm and extend our findings. It will notably be important to conduct stratified analysis that were not possible in our studies and that could reveal important factors such as ageing influencing the oxylipin signature and the risk of cardiometabolic diseases. Such large population studies are also mandatory for the clinical qualification of the oxylipin signature. Finally, although this was not an initial objective of the JPI-Oxygenate project, we observed high interindividual variability in the oxylipin profiles of the selected participants of our studies. Specifically investigating these aspects of population heterogeneity could help to better understand the variability of responses to dietary intervention (notably with omega 3 fatty acids) and pave the way to future personalized nutrition strategy.

Target group Authors Means of communication Hyperlink Pdf
Scientists, PhD students and students E. Koch, A. I. Ostermann, M. Mainka, C. Dalle, T. Konrad, C. Gladine, N. H. Schebb, Quantification of Total Oxylipins in Plasma – Challenges & Strategies for Hydrolysis and Solid Phase Extraction. 47th International Conference on Food Chemistry and Technology, Berlin, Germany, 2018. Poster    
Scientists, technicians, students Cécile Gladine*, The OXYGENATE project, Annual Human Nutrition day, Saint-Genes-Champanelle, May 2017 Presentation    
Scientists, Policy-makers, Industrials of the food industry Dominique Dardevet & Cécile Gladine*, From metabolic dysregulation to disease: research of biomarkers, Assises de Nutrition en Rhône-Alpes Auvergne, 2017 Presentation    
Scientists, PhD students and students Céline Dalle* and Malwina Mainka*, OXGENATE project – Overview and method optimization, Symposium Food Chemistry, Wuppertal, April 2017 Presentation    
Scientists, technicians, students Céline Dalle* & Cécile Gladine*, Oxylipins signature reflecting cardiometabolic status and diet quality, Annual Human Nutrition day, Saint-Genes-Champanelle, May 2018 Flash Poster    
Scientists, PhD students and students E Koch, AI. Ostermann, M Mainka, C Dalle, T Konrad, C Gladine, NH Schebb, Extraction of lipids and oxylipins from plasma for quantification of total oxylipins – Challenges and strategies, 7EWLM, Brussels, 2018 Poster    
Scientists, PhD students and students E. Koch, A. I. Ostermann, M. Mainka, C. Dalle, C. Gladine, N. H. Schebb, Challenges and strategies for the quantification of total oxylipins in biological samples, Regional conference of food chemistry, Wuppertal, Germany, 2019 Poster    
Scientists, PhD students and students E. Koch, A. I. Ostermann, M. Mainka, C. Dalle, C. Gladine, N. H. Schebb, Challenges and strategies for the quantification of total oxylipins in biological samples, Regional conference of food chemistry, Wuppertal, Germany, 2019 Poster    
Scientists, PhD students and students E. Koch, M. Mainka, A. I. Ostermann, L.-F. Fröhlich, C. Gladine, N. H. Schebb: Influence of the transitory stage during plasma generation on the pattern of total oxylipins. 48 Deutscher Lebensmittelchemikertag, 16.-18.09.2019 Dresden, Deutschland POster    
Scientists, Policy-makers, Industrials of the food industry C. Dalle, M. Mainka, J. Dalloux-Chioccioli, A.I. Ostermann, M. Rothe, J.W. Newman, J. Bertrand-Michel, N.H. Schebb, C. Gladine, Oxylipins signature to monitor the cardiometabolic status and its response to dietary intervention, 4th Assises de Nutrition en Rhône-Alpes Auvergne, Lyon, 2019 Presentation    
Scientists, PhD students and students C. Dalle, M. Mainka, J. Dalloux-Chioccioli, A.I. Ostermann, M. Rothe, J.W. Newman, J. Bertrand-Michel, C. Gladine, N.H. Schebb. Comparaison inter-laboratoires de profils d’oxylipines par lipidomique ciblée dans le cadre du projet JPI-OXYGENATE, RFMF, France, 2019 Poster    
Scientists, PhD students and students Dalle C, Lahaye C, Ostermann AI, Bosviel R, Barthélémy JC, Roche F, Féasson, L, Mazur A, Béchet D, Ruivard, M, Schebb, NH and Gladine, C, MS-based oxylipin targeted metabolomics: applications in clinical research, GERLI meeting, Compiègne, France, 2019 Presentation    
Scientists, PhD students and students M. Mainka, E. Koch, C. Dalle, J. Bertrand-Michel, C. Gladine and N. H. Schebb. Stability of total oxylipins influence of plasma generation and long-term storage. RFMF Metabomeeting, 22-24.01.2020 Toulouse, France Poster    
Scientists, PhD students and students C Dalle, M. Mainka, J. Dalloux-Chioccioli, A. I. Ostermann, M. Rothe, J. W. Newman, J. Bertrand-Michel, C. Gladine, N. H. Schebb: MS-based targeted metabolomics of eicosanoids and other oxylipins: analytical variability and interlaboratory comparison. RFMF Metabomeeting, 22-24.01.2020 Toulouse, France POster    
Scientists, PhD students and students K. M. Rund, M. Mainka, N. M. Hartung, N. Kampschulte, C. Dalle, M. Pétéra, J. Dalloux-Chioccioli, A. I. Ostermann, M. Rothe, J. Bertrand-Michel, J. W. Newman, C. Gladine, N. H. Schebb: Towards comparable results in oxylipin analysis. Winter Eicosanoid Conference, Virtual Meeting, 2020, October 15. 2020 Poster    
Scientists, industrials, PhD students and students Robustness and comparability of MS-based targeted metabolomics of total oxylipins: new verdict from the JPI-Oxygenate project. EU COST EpiLipidNet working group 2 Meeting, online, 2020 Presentation    
Scientists, industrials, PhD students and students Céline Dalle, Jérémy Tournayre, Malwina Mainka, Alicja Basiak-Rasała, Mélanie Pétéra, Jessica Dalloux-Chioccioli, Mélanie Deschasaux, Lucie Lécuyer, Sophie Lefèvre-Arbogast, Cécilia Samieri, Katarzyna Zatońska, Mads Fiil Hjorth, Arne Astrup, Justine Bertrand-Michel, Nils H. Schebb, Andrzej Szuba, Mathilde Touvier, John W. Newman, Cécile Gladine. Lipidomic profiling identifies consistent and performant oxylipin signatures of cardiometabolic syndrome. 9th International Singapore Lipid Symposium (iSLS9), online, 2021 Presentation    

Subjects

Features

Project number:
OXYGENATE
Duration: 100%
Duration: 100 %
2017
2021
Related subsidy round:
Project lead and secretary:
Gladine